ProCE Banner Activity

PARP Inhibitors in Advanced Prostate Cancer: Molecular Testing and Treatment at a Glance

PDF

Download this short resource of practical information on molecular testing recommendations and approved treatment options using PARP inhibitors for patients with advanced prostate cancer.

Released: May 24, 2024

Expiration: May 23, 2025

Share

Faculty

Karim Fizazi

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Joaquin Mateo

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Karim Fizazi, MD, PhD: consultant/advisor/speaker (paid to institution): Amgen, Astellas, AstraZeneca, Bayer, Clovis, Janssen, MacroGenics, Merck Sharp & Dohme, Novartis/Advanced Accelerator Applications, Pfizer, Sanofi; consultant/advisor/speaker: Arvinas, CureVac, Daiichi Sankyo, Orion.

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Joaquin Mateo, MD, PhD: consultant/advisor/speaker: Amgen, Amunix/Sanofi, AstraZeneca, Guardant Health, Nuage Therapeutics, Pfizer Oncology, Roche.